Phase 3 LIBRETTO-531 trial : Lilly’s Retevmo meets primary endpoint of PFS

Pallavi Madhiraju- August 24, 2023 0

Eli Lilly and Company (NYSE: LLY) unveiled exceptional results from their LIBRETTO-531 study of Retevmo (selpercatinib), setting a new standard in the treatment of advanced ... Read More

Lilly expands portfolio with $1.9bn acquisition of Versanis Bio

Pallavi Madhiraju- August 15, 2023 0

In a move marking a significant expansion in the biopharmaceutical sector, Eli Lilly and Company (Lilly) has successfully completed the acquisition of Versanis Bio, a ... Read More

Lilly wraps up Sigilon Therapeutics acquisition to amplify Type 1 diabetes research

Pallavi Madhiraju- August 15, 2023 0

Eli Lilly and Company (Lilly) has formally announced the culmination of its $309.6 million takeover of biopharma trailblazer, Sigilon Therapeutics, Inc. (NASDAQ: SGTX). This strategic ... Read More

Eli Lilly completes $2.4bn acquisition of DICE Therapeutics

Pallavi Madhiraju- August 10, 2023 0

Eli Lilly and Company (Lilly) has finalized its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE) for $2.4 billion, bolstering its immunology portfolio with the inclusion ... Read More

Eli Lilly Q2 2023 financial results highlight robust 28% revenue growth

Pallavi Madhiraju- August 9, 2023 0

Eli Lilly and Company (NYSE: LLY) unveiled their Q2 2023 financials, showcasing a 28% revenue enhancement, predominantly driven by volume growth from Mounjaro, Verzenio, Jardiance, ... Read More

LIBRETTO-431 study: Lilly’s Retevmo emerges as potential first-line treatment for RET fusion-positive NSCLC

Pallavi Madhiraju- August 6, 2023 0

Eli Lilly and Company (NYSE: LLY) has unveiled top-line results from the LIBRETTO-431 study, which focused on the assessment of Retevmo against platinum-based chemotherapy plus ... Read More

Amber Bio raises $26m to advance first-of-its-kind RNA editing platform

Pallavi Madhiraju- August 4, 2023 0

Amber Bio, a trailblazing biotechnology company, has launched with an oversubscribed $26 million seed financing round to pioneer multi-kilobase gene editing platforms. This innovative approach ... Read More

Eli Lilly’s Tirzepatide triumphs in Phase 3 weight loss studies

Pallavi Madhiraju- July 27, 2023 0

Eli Lilly and Company has unveiled the results of two Phase 3 tirzepatide studies (SURMOUNT-3 and SURMOUNT-4) targeting adults with obesity or overweight with weight-related ... Read More

Lilly’s donanemab shows encouraging results in Phase 3 Alzheimer’s trial

Pallavi Madhiraju- July 19, 2023 0

Eli Lilly and Company (Lilly) revealed complete results from its Phase 3 TRAILBLAZER-ALZ 2 study at the 2023 Alzheimer's Association International Conference (AAIC), indicating that ... Read More

Lilly to acquire clinical-stage biopharma company Versanis Bio

Pallavi Madhiraju- July 14, 2023 0

American pharma giant Eli Lilly and Company (Lilly) and Versanis Bio have announced a definitive agreement in which the former will acquire the privately-held clinical-stage ... Read More

123456...1040 / 94 Posts